Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.48 |
| ▸ | TGM1 | P22735 | 13/20 | 0.48 |
| ▸ | F13A1 | P00488 | 12/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453894 | 0.96 | TGM2 (0.47) | TGM2TGM1F13A1PIK3CDAURKA | |
| SCHEMBL5447139 | 0.86 | TGM2 (0.60) | TGM2TGM1F13A1 | |
| SCHEMBL14501662 | 0.86 | AXL (0.53) | TGM2TGM1F13A1AXLTYRO3 | |
| SCHEMBL5452245 | 0.85 | F13A1 (0.47) | TGM2TGM1F13A1PIK3CDAURKA | |
| SCHEMBL5440818 | 0.85 | F13A1 (0.47) | TGM2TGM1F13A1PIK3CDAURKA | |
| SCHEMBL5446141 | 0.85 | TGM2 (0.47) | TGM2TGM1F13A1NAMPT | |
| SCHEMBL5437791 | 0.85 | ALDH1A1 (0.43) | TGM2TGM1F13A1SMN1; SMN2 | |
| SCHEMBL5435040 | 0.82 | TGM2 (0.48) | TGM2TGM1F13A1PIK3CDAURKA | |
| SCHEMBL14490207 | 0.81 | TGM2 (0.64) | TGM2TGM1F13A1SYK | |
| SCHEMBL5434924 | 0.80 | SYK (0.59) | TGM2TGM1F13A1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TGM2 1975/4885TGM1 904/4885F13A1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.